Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Nu-Med Plus (NUMD) Return on Equity (2016 - 2021)

Nu-Med Plus' Return on Equity history spans 9 years, with the latest figure at 34.46% for Q3 2021.

  • Quarterly results put Return on Equity at 34.46% for Q3 2021, up 3992.0% from a year ago — trailing twelve months through Sep 2021 was 34.46% (up 3992.0% YoY), and the annual figure for FY2020 was 41.6%, down 4804.0%.
  • Return on Equity for Q3 2021 was 34.46% at Nu-Med Plus, up from 16.59% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 149.27% in Q1 2018 to a low of 151.21% in Q2 2018.
  • The 5-year median for Return on Equity is 0.0% (2017), against an average of 1.53%.
  • The sharpest move saw Return on Equity tumbled -15007bps in 2018, then skyrocketed 15695bps in 2019.
  • Year by year, Return on Equity stood at 63.52% in 2017, then crashed by -115bps to 9.62% in 2018, then skyrocketed by 131bps to 3.02% in 2019, then plummeted by -294bps to 5.88% in 2020, then skyrocketed by 686bps to 34.46% in 2021.
  • According to Business Quant data, Return on Equity over the past three periods came in at 34.46%, 16.59%, and 6.77% for Q3 2021, Q2 2021, and Q1 2021 respectively.